


I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: October 3, 2008

Signature: 
(Katherine L. Neville)

Docket No.: 30610/39385A
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Todd C. Zankel et al.

Application No.: 10/588,425

Confirmation No.: 5100

Filed: June 6, 2007

Art Unit: 1657

For: Manufacture of Highly Phosphorylated
Lysosomal Enzymes and Uses Thereof

Examiner: Kailash C. Srivastava

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Applicant submits herewith copies of non-patent literature in accordance with 37 CFR 1.98(a)(2).

Pursuant to 37 CFR 1.704(d), the documents identified on the attached PTO/SB/08 were first cited in any communication from a foreign patent office in a counterpart application and this communication was not received by any individual

designated in 37 CFR 1.56(c) more than three months prior to the filing of this information disclosure statement.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 30610/39385A.

Dated: October 3, 2008

Respectfully submitted,

By Katherine L. Neville

Katherine L. Neville
Registration No.: 53,379
MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Attorney for Applicant